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Background: Despite surgical adjuncts, paralysis remains a devastating complication after thoracoabdominal aortic
interventions. Dexmedetomidine, a selective -2a agonist commonly used for sedation in the critical care setting, has been
shown to have protective effects against ischemia-reperfusion injuries in multiple organ systems. We hypothesized that
treatment with dexmedetomidine would attenuate spinal cord ischemia-reperfusion injury via -2a receptor activation.
Methods: Adult C57BL/6 mice underwent sternotomy, followed by occlusion of the aortic arch for 4 minutes. Eight
experimental mice received pretreatment with intraperitoneal dexmedetomidine (25 g/kg) and at 12-hour intervals
after reperfusion. Eight control mice received an equivalent amount of 0.9% normal saline. Five mice underwent the same
procedure with dexmedetomidine (25 g/kg) and atipamezole (250 g/kg), an -2a receptor antagonist. Functional
analysis of the mice was obtained at 12-hour intervals and scored using the Basso Mouse Scale for Locomotion until 60
hours. All mice were euthanized at 60 hours. Their spinal cords were removed en bloc and were stained with hematoxylin
and eosin to assess cytoarchitecture and neuronal viability.
Results:Mice treated with the -2a agonist demonstrated preserved motor function compared with ischemic controls and
with mice treated with the -2a antagonist in addition to the agonist. Functional differences in the dexmedetomidine
group were statistically significant from 24 hours through the remainder of the experiment (P < .05). In addition, the
treated mice had preserved cytoarchitecture, decreased vacuolization, and improved neuronal viability compared with
ischemic control mice and mice concurrently treated with atipamezole, the dexmedetomidine -2a antagonist.
Conclusions: Treatment of mice with the -2a agonist dexmedetomidine preserves motor function and neuronal viability
after aortic cross-clamping. In addition, mice exhibited almost complete reversal of the protective effect with the
administration of the -2a receptor antagonist atipamezole. Dexmedetomidine appears to attenuate spinal cord
ischemia-reperfusion injury via -2a receptor-mediated agonism. (J Vasc Surg 2012;56:1398-1402.)
Clinical Relevance: There remains a significant risk of paraplegia after thoracoabdominal aortic interventions. This
complication is devastating to the patient and the health care system. Pharmacologic adjuncts to further decrease this
complication have been studied; however, few viable options exist. The -2a agonists have been shown to improve
outcomes after strokes but have not been studied in spinal cord ischemia. We show that dexmedetomidine, a commonly
used -2a agonist in the operating room, can preserve neurologic function in mice after aortic cross-clamping. Although
the protective mechanism of dexmedetomidine remains unknown, it might prove to be beneficial in reducing the
incidence of paraplegia after aortic interventions.
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pParaplegia continues to complicate thoracoabdominal
intervention, with devastating consequences for patients.
Although advancements in surgical adjuncts, such as hypo-
thermic circulatory arrest, left heart bypass, intercostal ar-
tery reimplantation, and lumbar drains, have decreased the
incidence of this complication, spinal cord injury still occurs
in up to 14% of patients.1 Pharmacologic adjuncts to re-
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1398uce this complication have been long sought-after, with
ew proven strategies filtering up to clinical use.
Spinal cord injury after these interventions results from
complex milieu of overlapping pathologies. Ischemia
esulting from some period of absent or impaired perfusion
uring aortic cross-clamping leads to a metabolic neuronal
njury. With reperfusion, restoration of blood flow occurs
nd amplifies the inflammatory response to the metabolic
njury, which can convert reversible injury to lethal injury in
ome neurons.2,3
Dexmedetomidine is a highly selective -2a receptor
gonist commonly used as a sedative in the operating room
nd intensive care unit. The beneficial neuroprotective
ffects of dexmedetomidine have been well-documented in
odels of stroke4-6 and traumatic spinal cord injury7,8 and
dditional tissue protection has been shown in cardiac,9
ulmonary,10,11 and renal12,13 models. No studies to date
ave investigated the effects of dexmedetomidine after
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Volume 56, Number 5 Bell et al 1399spinal cord ischemia-reperfusion. The mechanism by which
dexmedetomidine provides its neuroprotection is currently
unknown. We hypothesized that treatment with dexme-
detomidine will attenuate spinal cord ischemia-reperfusion
injury after aortic occlusion in a fashion that is specific to
selective -2a receptor activation.
METHODS
All experiments were approved by the Animal Care
and Use Committee at the University of Colorado at
Denver and Health Sciences Center. This investigation
conformed to the Guide for the Care and Use of Labora-
tory Animals (US National Institutes of Health publica-
tion No. 85-23, National Academy Press, Washington
DC, revised 1996).
Animal procedures. Twenty-three C57BL/6 male
mice, 12 to 20 weeks old, were obtained from Jackson
Laboratories (Bar Harbor, Me). Mice were placed supine
and anesthetized using 2% isoflurane. The aortic arch was
exposed through a cervicothoracic approach, as previously
described.14,15 Under direct visualization, the aortic arch
was cross-clamped between the left common carotid artery
and the left subclavian artery. An additional clamp was
placed on the subclavian artery to minimize collateral flow.
Occlusion was confirmed by a laser Doppler blood flow
monitor (Moor Instruments, Axminster, Devon, UK). A
90% decrease in distal aortic flow measured at the femoral
artery was observed and maintained for 4 minutes. During
the procedure, the core body temperature was maintained
at 36.5°  0.5°C using a rectal temperature probe and
automatic temperature-adjusting bed (Vestavia Scientific,
Birmingham, Ala).
Animals in the treatment group (n  8) received intra-
peritoneal dexmedetomidine (25 g/kg) 30 minutes before
aortic occlusion and at 12-hour intervals after reperfusion.
Additional mice (n 5) were treated with dexmedetomidine
(25 g/kg) and atipamezole (250 g/kg), a selective -2a
antagonist, preoperatively and at 12-hour intervals after
surgery. The dosages of agonist and antagonist were chosen
based on previous ischemia-reperfusion studies.12 The isch-
emic control group (n 8) received equivalent amounts of
0.9% normal saline before the procedure. Sham mice (n 
2) underwent aortic arch exposed through the same proce-
dure but no aortic-cross clamping was done. All animals
were euthanized at 60 hours after reperfusion and their
spinal cords were harvested for analysis.
Functional locomotor scores. After reperfusion,
neurologic function was quantified at 0, 12, 24, 36, 48, and
60 hours using the Basso Mouse Scale for Locomotion.16
Scoring ranges from 0 for complete paraplegia to 9 for
normal function.
Histologic analysis and neuronal quantification.
The vertebral column was removed en bloc from T-8
through L-3. The spinal cord was removed from the verte-
bral column by injection of phosphate-buffered saline (pH
7.4) into the spinal column. Spinal cords were transferred
to 10% formalin, where they remained for at least 24 hours
before being embedded in paraffin, sectioned, and stained pith hematoxylin and eosin. Sections were evaluated for
euronal viability by a blinded observer and quantified as
eurons per microscopic field. Neurons within the anterior
orn that contained prominent nucleoli and loose chroma-
in were considered normal.
Statistical analysis. Statistical analysis was performed
sing analysis of variance with the Fisher least significant
ifference post hoc test. Data were analyzed with StatView
oftware (SAS Institute Inc, Cary, NC) and are presented as
ean  standard error. A value of P  .05 was considered
ignificant for statistical comparisons.
ESULTS
Neurologic outcomes. All mice exhibited a func-
ional neurologic deficit after aortic occlusion. Mice treated
ith dexmedetomidine had preserved neurologic function
ompared with ischemic control mice (Fig 1). Statistical
ignificance was noted between the -2a agonist and isch-
mic controls from 24 hours of reperfusion through the
tudy period. Animals treated with the -2a agonist and
-2a antagonist exhibited functional decline that was not
ignificantly different from ischemic controls but was sig-
ificantly worse than -2a agonist alone beginning at 24
ours of reperfusion through the study period.
Histologic analysis and neuronal viability. Mice
reated with dexmedetomidine showed preserved cyto-
rchitecture similar to shammice. Untreatedmice andmice
reated with both -2a agonist and antagonist had
hrunken nuclei andmore vacuolization compared with the
reatment group, indicating a greater degree of inflamma-
ion and cellular injury (Fig 2).
When compared with sham mice, all groups had a
ignificant reduction in the number of viable anterior
orn neurons (Fig 3). Dexmedetomidine, when given
lone, significantly preserved neuronal viability com-
ig 1. Functional outcomes of mice after ischemia and reperfu-
ion, with and without dexmedetomidine (Dex) and atipamezole
reatment, are presented. Mice treated with dexmedetomidine
howed preserved functional outcomes compared with ischemic
ontrols. Mice that received dexmedetomidine in addition to
tipamezole showed function decline similar to ischemic controls.
P  .05 for statistical variance. Data are presented as mean and
tandard error (error bars).ared with ischemic control mice and the mice that
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treatment. In addition, there was no significant differ-
ence observed in the ischemic control mice and the
combined treatment mice.
DISCUSSION
The current data demonstrate a murine model of the
delayed paralysis seen clinically after thoracoabdominal aor-
tic surgery. Administration of dexmedetomidine before
surgery preserved neurologic function and cytoarchitecture
after aortic occlusion in mice via -2a receptor activation.
Furthermore, the loss of this protection with the addition
of an -2a receptor antagonist demonstrates the specificity
of this protection to the -2a receptor.
These data in the spinal cord corroborate protective
findings of dexmedetomidine in other organ systems. Pres-
ervation of motor function and neuronal viability are dem-
onstrated in the spinal cords of treated mice. These findings
remain consistent with protection not only against ischemic
insults but also against other systemic proinflammatory
states such as sepsis17,18 and arthritis.19 Multiple mecha-
nisms for dexmedetomidine’s neuroprotection have been
postulated; however, the exact mechanism remains un-
Fig 2. Hematoxylin and eosin-stained images of murin
untreated, (C) dexmedetomidine treatment, and (D) co
Mice in the control and combined treatment groups had
increased vacuolization compared with sham and dex
inflammation and cellular injury. Images are shown at ori
are at original magnification.known. 1Although the injury after thoracoabdominal aortic sur-
ery is broadly classified as “spinal cord ischemia-reperfusion,”
t appears to result from the two overlapping yet distinctly
ifferent injuries. Initially, ischemia from the low-flow state
uring aortic cross-clamping produces metabolic derange-
ent, with apoptosis in some neurons. The restoration of
lood flow at reperfusion amplifies the inflammatory re-
ponse, resulting in delayed progression of neuronal injury.
his dual-pronged mechanism of injury parallels what is
een clinically. Paralysis after surgery occurs in a bimodal
istribution, and neurologic function in many patients is
ntact immediately after surgery.20 For pharmacologic ad-
uncts to be effective, they must protect against the initial
etabolic derangement from ischemia or temper reperfu-
ion effects.
Whether dexmedetomidine protects against the meta-
olic or inflammatory injuries remains unclear. Several
athways of protection through ischemic tolerance have
een proposed. Dexmedetomidine administration upregu-
ates multiple antiapoptotic proteins, such as Bcl-2 andMdm-
,5 in central nervous system (CNS) tissue after ischemia. In
ddition, dexmedetomidine induces hypoxia-inducible factor
nal cords from each group at 60 hours: (A) sham, (B)
ed treatment with dexmedetomidine and atipamezole.
ken nuclei, poor gray-white matter differentiation, and
tomidine treated mice, denoting a greater degree of
magnification40 magnification; the images in the boxe spi
mbin
shrun
mede
ginal- expression4 in the brain after ischemia. Any of these
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tion.
Other mechanisms, such as attenuation of excitotox-
icty, have been proposed.21 However, attenuation of the
reperfusion mechanism has also been postulated as a result
of dexmedetomidine-induced anti-inflammatory character-
istics. Rodent models of sepsis show improved survival and
a significant attenuation of proinflammatory cytokines with
dexmedetomidine.17,18 In traumatic spinal cord models,
dexmedetomidine reduced expression of tumor necrosis
factor- and interleukin-6.7 These initial data using dexme-
detomidine for neuroprotection from spinal cord ischemia-
reperfusion injury do not yet elucidate how its protective
effect occurs, but the mechanism will be studied further
using this model.
Controversy in other models remains regarding whether
dexmedetomidine-derived neuroprotection results from -2a
receptor agonism or if other receptors are implicated. The
-2a receptors are ubiquitously expressed in theCNS.22 Their
presence inmultiple cell types, including neurons, microglia,
and astrocytes, has been described.23 Activation of these
receptors in the CNS has been implicated in modulation of
intracellular calcium24 and norepinephrine release.25 Al-
though dexmedetomidine is a highly selective -2a agonist,
it also binds to and activates imidazoline receptors.26 Acti-
vation of these receptors likely explains dexmedetomidine
upregulation of hypoxia-inducible factor-1 and vascular
endothelial growth factor after hypoxia in the CNS. Other
-2a receptor agonists, such as clonidine, have shown sim-
Fig 3. After 60 hours of reperfusion, the anterior horns of the
spinal cords were assessed for neuronal viability, calculated as
neurons per microscopic field. Sham mice had significantly more
viable neurons than the other groups. The mice treated with
dexmedetomidine alone had significantly more anterior horn neu-
rons compared with ischemic control mice and mice that received
combined treatment with dexmedetomidine (Dex) and atipam-
ezole. No significant difference was noted between the ischemic
control group and the combined treatment group. Data represent
mean standard error (error bars). *P .05 compared with sham
control; P  .05 compared with dexmedetomidine treatment
alone.ilar neuroprotective characteristics.25,27,28Atipamezole is a highly selective -2a receptor antago-
ist used clinically to reverse the sedative effects of dexme-
etomidine. These data show nearly complete reversal of
europrotection with administration atipamezole, a spe-
ific -2a antagonist. This is consistent with -2a–mediated
europrotection. However, the extent to which atipam-
zole interacts with imidazoline receptors is unclear.
Although multiple pharmacologic agents have been
tudied for spinal cord protection,29 few can be as easily
ranslated into the clinical setting as dexmedetomidine.
exmedetomidine can be administered to patients under-
oing aortic surgery without concern for severe cardiovas-
ular side effects. In addition, unlike many inhaled anes-
hetics, dexmedetomidine can be given without an
nfluence on motor or sensory evoked potentials.30
ONCLUSIONS
Dexmedetomidine exerts neuroprotective effects against
pinal cord ischemia-reperfusion injury after aortic occlu-
ion in mice. These affects appear to be mediated by -2a
drenergic receptor agonism. Although further studies
eed to be conducted to determine its exact mechanism,
exmedetomidine administration might prove to be bene-
cial in reducing the incidence of paraplegia after thoraco-
bdominal aortic surgery.
UTHOR CONTRIBUTIONS
onception and design: MB, FP, PS, XM, DF, TR
nalysis and interpretation: MB, FP, PS, XM, VA, MW,
DF, TR
ata collection: MB, FP, PS, TR, VA
riting the article: MB, FP, PS, DF, TR
ritical revision of the article: MB, FP, PS, XM, VA, MW,
DF, TR
inal approval of the article: MB, FP, PS, XM, VA, MW,
DF, TR
tatistical analysis: MB, PS, FP, VA,TR
btained funding: PF, DF, BR
verall responsibility: MB
EFERENCES
1. Conrad MF, Ye JY, Chung TK, Davison JK, Cambria RP. Spinal cord
complications after thoracic aortic surgery: Long-term survival and
functional status varies with deficit severity. J Vasc Surg 2008;48:47-53.
2. Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology
of apoptosis in ischemia and reperfusion. J Invest Surg 2005;18:335-50.
3. Harukuni I, Bhardwaj A. Mechanisms of brain injury after global
cerebral ischemia. Neurol Clin 2006;24:1-21.
4. Zhang F, Ding T, Yu L, Zhong Y, Dai H, Yan M. Dexmedetomidine
protects against oxygen-glucose deprivation-induced injury through
the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells.
J Pharm Pharmacol 2012;64:120-7.
5. Engelhard K, Werner C, Eberspa E, Bachl M, Blobner M, Hildt E, et al.
The effect of the 2 -agonist dexmedetomidine and the N-methyl-D
aspartate antagonist S() ketamine on the expression of apoptosis-
regulating Proteins after incomplete cerebral ischemia and reperfusion
in rats. Neurosurg Anesth 2003;96:524-31.
6. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD,
Franks NP, et al. Dexmedetomidine produces its neuroprotective
effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol
2004;502:87-97.
22
2
2
2
2
2
2
2
2
3
JOURNAL OF VASCULAR SURGERY
November 20121402 Bell et al7. Can M, Gul S, Bektas S, Hanci V, Acikgoz S. Effects of dexmedetomi-
dine or methylprednisolone on inflammatory responses in spinal cord
injury. Acta Anaesthesiol Scand 2009;53:1068-72.
8. Gul S, Hanci V, Bahadir B, Acikgoz S, Bektas S, Ankarali H, et al. The
effectiveness of dexmedetomidine in experimental spinal cord injury
compared to methylprednisolone in rats. J Clin Neurosci 2010;17:
490-4.
9. Okada H, Kurita T, Mochizuki T, Morita K, Sato S. The cardioprotec-
tive effect of dexmedetomidine on global ischaemia in isolated rat
hearts. Resuscitation 2007;74:538-45.
10. Gu J, Chen J, Xia P, Tao G, Zhao H, Ma D. Dexmedetomidine
attenuates remote lung injury induced by renal ischemia-reperfusion in
mice. Acta Anaesthesiol Scand 2011;55:1272-8.
11. Yang CL, Chen CH, Tsai PS, Wang TY, Huang CJ. Protective effects of
dexmedetomidine-ketamine combination against ventilator-induced
lung injury in endotoxemia rats. J Surg Res 2011;167:e273-81.
12. Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, et al.
Dexmedetomidine provides renoprotection against ischemia-
reperfusion injury in mice. Crit Care 2011;15:R153.
13. Kocoglu H, Ozturk H, Ozturk H, Yilmaz F, Gulcu N. Effect of
dexmedetomidine on ischemia-reperfusion injury in rat kidney: A his-
topathologic study. Ren Fail 2009;31:70-4.
14. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP,
Moskowitz MA, et al. Spinal cord ischemia. Development of a model in
the mouse. Stroke 2000;31:208-13.
15. Smith PD, Puskas F, Meng X, Cho D, Cleveland JC, Weyant MJ, et al.
Ischemic dose–response in the spinal cord: Both immediate and delayed
paraplegia. J Surg Res 2011;7:1-7.
16. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM,
Popovich PG. Basso mouse scale for locomotion detects differences in
recovery after spinal cord injury in five common mouse strains. J Neu-
rotrauma 2006;23:635-59.
17. Taniguchi T, Kurita A, Kobayashi K, Yamamoto K, Inaba H. Dose- and
time-related effects of dexmedetomidine onmortality and inflammatory
responses to endotoxin-induced shock in rats. J Anesth 2008;22:221-8.
18. Qiao H, Sanders RD, Ma D, Wu X, Maze M. Sedation improves early
outcome in severely septic Sprague Dawley rats. Crit Care 2009;13:
R136.
19. Xu B, Zhang WS, Yang JL, Lû N, Deng XM, Xu H, et al. Evidence for
suppression of spinal glial activation by dexmedetomidine in a rat model
of monoarthritis. Clin Exp Pharmacol Physiol 2010;37:e158-66. S0. Wong DR, Coselli JS, Amerman K, Bozinovski J, Carter SA, Vaughn
WK, et al. Delayed spinal cord deficits after thoracoabdominal aortic
aneurysm repair. Ann Thorac Surg 2007;83:1345-55.
1. Chiu KM, Lin TY, Lu CW, Wang SJ. Inhibitory effect of glutamate
release from rat cerebrocortical nerve terminals by 2 adrenoceptor
agonist dexmedetomidine. Eur J Pharmacol 2011;670:137-47.
2. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist
binding sites in the rat and human central nervous system: Analysis of
some functional, anatomic correlates of the pharmacologic effects of
clonidine and related adrenergic agents. Brain Res 1984;319:69-101.
3. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in
brain: cellular gene expression and effects on astrocytic metabolism and
[Ca(2)]i. Neurochem Int 2010;57:411-20.
4. Dong CJ, Guo Y, Wheeler L, Hare WA. Alpha2 adrenergic receptor-
mediated modulation of cytosolic Ca signals at the inner plexiform
layer of the rat retina. Invest Ophthalmol Vis Sci 2007;48:1410-5.
5. Mori K, Ozaki E, Zhang B, Yang L, Yokoyama A, Takeda I, et al. Effects
of norepinephrine on rat cultured microglial cells that express alpha1,
alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology
2002;43:1026-34.
6. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline their
pharmacology and therapeutic role. J Anesth 1999;54:146-65.
7. Zhang Y. Clonidine preconditioning decreases infarct size and improves
neurological outcome from transient forebrain ischemia in the rat.
Neuroscience 2004;125:625-31.
8. Dean JM, George S, Naylor AS, Mallard C, Gunn AJ, Bennet L. Partial
neuroprotection with low-dose infusion of the alpha2-adrenergic recep-
tor agonist clonidine after severe hypoxia in preterm fetal sheep. Neu-
ropharmacology 2008;55:166-74.
9. Reece T. The role of pharmacology in spinal cord protection during
thoracic aortic reconstruction. Semiin Thorac Cardiovasc Surg 2003;
15:365-77.
0. Bala E, Sessler DI, Nair DR, McLain R, Dalton JE, Farag E. Motor and
somatosensory evoked potentials are well maintained in patients given
dexmedetomidine during spine surgery. Anesthesiology 2008;109:
417-25.ubmitted Jan 19, 2012; accepted Apr 5, 2012.
